The Trump administration is reportedly considering a proposal to charge patent holders a fee based on the value of their patents, potentially ranging from 1% to 5%. Experts have raised serious concerns, arguing that determining patent value is highly complex and subjective, and such a fee could discourage innovation, especially among small companies.
Commerce Department officials are discussing charging patent holders 1% to 5% of their overall patent value, a shift that could dramatically increase fees
View referenced article
Author(s)
Related Insights
July 21, 2026
Foley Viewpoints
Is Your Company IPO-Ready? The 12-Month Checklist
Traditional IPOs raised roughly $114 billion in the first half of 2026, more than seven times the total from the same period last year. Sixty-five companies went public, nearly double the prior year's count, and most opened above their offer price. Boards have noticed, and the question I hear most often now is whether the company is ready.
July 20, 2026
Foley Viewpoints
The Texas Business Court Issues Its First Published Opinion on a TCPA Motion to Dismiss
July 20, 2026
Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor
In our companion article, Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus, we analyzed two recent Federal Circuit decisions that offer complementary guidance on a recurring question in patent law: what must a patent specification disclose to satisfy written description and enablement under 35 U.S.C. § 112 when the claimed invention is the new use of a genus of known compounds or compositions?